Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open Trial
The aim of this open-label study was to assess the therapeutic benefits, response pattern, and safety of sertraline in children with social anxiety disorder. Fourteen outpatient subjects with a primary Axis I diagnosis of social anxiety disorder were treated in an 8-week open trial of sertraline. Di...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 2001-05, Vol.40 (5), p.564-571 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 571 |
|---|---|
| container_issue | 5 |
| container_start_page | 564 |
| container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
| container_volume | 40 |
| creator | COMPTON, SCOTT N. GRANT, PAUL J. CHRISMAN, ALLAN K. GAMMON, PATRICIA JENEY BROWN, VICKI L. MARCH, JOHN S. |
| description | The aim of this open-label study was to assess the therapeutic benefits, response pattern, and safety of sertraline in children with social anxiety disorder.
Fourteen outpatient subjects with a primary Axis I diagnosis of social anxiety disorder were treated in an 8-week open trial of sertraline. Diagnostic and primary outcome measures included the Anxiety Disorders Interview Schedule for Children, Clinical Global Impressions scale (CGI), Social Phobia and Anxiety Inventory for Children, and a standardized behavioral avoidance test.
As measured by the CGI (Improvement subscale), 36% (5/14) of subjects were classified as treatment responders and 29% (4/14) as partial responders by the end of the 8-week trial. A significant clinical response appeared by week 6. Self-report and behavioral measures showed significant clinical improvement into normal range across all domains measured. The mean dose of sertraline was 123.21 ± 37.29 mg per day. Sertraline was generally well tolerated.
In open treatment, sertraline resulted in significant improvement in symptoms of childhood social anxiety disorder. Absolute response rates varied depending on rating scales used. Findings from this study are sufficiently strong to warrant a future multisite, randomized, double-blind, placebo-controlled trial of sertraline for treatment of childhood social anxiety disorder. |
| doi_str_mv | 10.1097/00004583-200105000-00016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70838471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890856709606870</els_id><sourcerecordid>73091482</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-b78bbcbf0d953c6ec733283b3a4cf81f1ae038ffcd9758e02540060eb044ceaa3</originalsourceid><addsrcrecordid>eNqFkF1LHDEUhkNR6mr7F0pQ6N3oySSZZHq3rh8VBKFaehkyyRmMzGa2yWzRf2_sbhV6YyCEJM97eHkIoQyOGbTqBMoSUvOqBmAgy60qmzUfyIzJWlVSML1DZqBbqLRs1B7Zz_nhBVFafyR7jHHRKmAz8uMW05TsECLSEOniPgw-YaQ2ejr344DZYZwy_RWme3o7umAHOo-PAacnehbymDymb-WF3qxK6i6V_09kt7dDxs_b84D8vDi_W3yvrm8urxbz68oJ2UxVp3TXua4H30ruGnSK81rzjlvhes16ZhG47nvnWyU1Qi0FQAPYgRAOreUH5Otm7iqNv9eYJ7MMpe0w2IjjOhsFmmuhWAEP_wMfxnWKpZupWS1b1TSiQHoDuTTmnLA3qxSWNj0ZBuZFuvkn3bxKN3-ll-iX7fx1t0T_FtxaLsDRFrDZ2aFPNrqQX7m20UypQp1uKCzS_gRMJruA0aEPCd1k_Bje7_IM3ticHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212597664</pqid></control><display><type>article</type><title>Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open Trial</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Journals@Ovid Complete</source><creator>COMPTON, SCOTT N. ; GRANT, PAUL J. ; CHRISMAN, ALLAN K. ; GAMMON, PATRICIA JENEY ; BROWN, VICKI L. ; MARCH, JOHN S.</creator><creatorcontrib>COMPTON, SCOTT N. ; GRANT, PAUL J. ; CHRISMAN, ALLAN K. ; GAMMON, PATRICIA JENEY ; BROWN, VICKI L. ; MARCH, JOHN S.</creatorcontrib><description>The aim of this open-label study was to assess the therapeutic benefits, response pattern, and safety of sertraline in children with social anxiety disorder.
Fourteen outpatient subjects with a primary Axis I diagnosis of social anxiety disorder were treated in an 8-week open trial of sertraline. Diagnostic and primary outcome measures included the Anxiety Disorders Interview Schedule for Children, Clinical Global Impressions scale (CGI), Social Phobia and Anxiety Inventory for Children, and a standardized behavioral avoidance test.
As measured by the CGI (Improvement subscale), 36% (5/14) of subjects were classified as treatment responders and 29% (4/14) as partial responders by the end of the 8-week trial. A significant clinical response appeared by week 6. Self-report and behavioral measures showed significant clinical improvement into normal range across all domains measured. The mean dose of sertraline was 123.21 ± 37.29 mg per day. Sertraline was generally well tolerated.
In open treatment, sertraline resulted in significant improvement in symptoms of childhood social anxiety disorder. Absolute response rates varied depending on rating scales used. Findings from this study are sufficiently strong to warrant a future multisite, randomized, double-blind, placebo-controlled trial of sertraline for treatment of childhood social anxiety disorder.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1097/00004583-200105000-00016</identifier><identifier>PMID: 11349701</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>Adolescent ; Antidepressive Agents - administration & dosage ; Antidepressive Agents - therapeutic use ; Anxiety ; Anxiety Disorders - drug therapy ; Biological and medical sciences ; Child ; Children & youth ; Clinical trials ; Drug Administration Schedule ; Female ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Pharmaceuticals ; Pharmacology. Drug treatments ; pharmacotherapy ; preadolescent ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; sertraline ; Sertraline - administration & dosage ; Sertraline - therapeutic use ; Social Adjustment ; social anxiety disorder ; Treatment Outcome</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2001-05, Vol.40 (5), p.564-571</ispartof><rights>2001 The American Academy of Child and Adolescent Psychiatry</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins May 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-b78bbcbf0d953c6ec733283b3a4cf81f1ae038ffcd9758e02540060eb044ceaa3</citedby><cites>FETCH-LOGICAL-c456t-b78bbcbf0d953c6ec733283b3a4cf81f1ae038ffcd9758e02540060eb044ceaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0890856709606870$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,30978,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=968177$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11349701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>COMPTON, SCOTT N.</creatorcontrib><creatorcontrib>GRANT, PAUL J.</creatorcontrib><creatorcontrib>CHRISMAN, ALLAN K.</creatorcontrib><creatorcontrib>GAMMON, PATRICIA JENEY</creatorcontrib><creatorcontrib>BROWN, VICKI L.</creatorcontrib><creatorcontrib>MARCH, JOHN S.</creatorcontrib><title>Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open Trial</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>The aim of this open-label study was to assess the therapeutic benefits, response pattern, and safety of sertraline in children with social anxiety disorder.
Fourteen outpatient subjects with a primary Axis I diagnosis of social anxiety disorder were treated in an 8-week open trial of sertraline. Diagnostic and primary outcome measures included the Anxiety Disorders Interview Schedule for Children, Clinical Global Impressions scale (CGI), Social Phobia and Anxiety Inventory for Children, and a standardized behavioral avoidance test.
As measured by the CGI (Improvement subscale), 36% (5/14) of subjects were classified as treatment responders and 29% (4/14) as partial responders by the end of the 8-week trial. A significant clinical response appeared by week 6. Self-report and behavioral measures showed significant clinical improvement into normal range across all domains measured. The mean dose of sertraline was 123.21 ± 37.29 mg per day. Sertraline was generally well tolerated.
In open treatment, sertraline resulted in significant improvement in symptoms of childhood social anxiety disorder. Absolute response rates varied depending on rating scales used. Findings from this study are sufficiently strong to warrant a future multisite, randomized, double-blind, placebo-controlled trial of sertraline for treatment of childhood social anxiety disorder.</description><subject>Adolescent</subject><subject>Antidepressive Agents - administration & dosage</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Anxiety</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Children & youth</subject><subject>Clinical trials</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmaceuticals</subject><subject>Pharmacology. Drug treatments</subject><subject>pharmacotherapy</subject><subject>preadolescent</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>sertraline</subject><subject>Sertraline - administration & dosage</subject><subject>Sertraline - therapeutic use</subject><subject>Social Adjustment</subject><subject>social anxiety disorder</subject><subject>Treatment Outcome</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkF1LHDEUhkNR6mr7F0pQ6N3oySSZZHq3rh8VBKFaehkyyRmMzGa2yWzRf2_sbhV6YyCEJM97eHkIoQyOGbTqBMoSUvOqBmAgy60qmzUfyIzJWlVSML1DZqBbqLRs1B7Zz_nhBVFafyR7jHHRKmAz8uMW05TsECLSEOniPgw-YaQ2ejr344DZYZwy_RWme3o7umAHOo-PAacnehbymDymb-WF3qxK6i6V_09kt7dDxs_b84D8vDi_W3yvrm8urxbz68oJ2UxVp3TXua4H30ruGnSK81rzjlvhes16ZhG47nvnWyU1Qi0FQAPYgRAOreUH5Otm7iqNv9eYJ7MMpe0w2IjjOhsFmmuhWAEP_wMfxnWKpZupWS1b1TSiQHoDuTTmnLA3qxSWNj0ZBuZFuvkn3bxKN3-ll-iX7fx1t0T_FtxaLsDRFrDZ2aFPNrqQX7m20UypQp1uKCzS_gRMJruA0aEPCd1k_Bje7_IM3ticHw</recordid><startdate>20010501</startdate><enddate>20010501</enddate><creator>COMPTON, SCOTT N.</creator><creator>GRANT, PAUL J.</creator><creator>CHRISMAN, ALLAN K.</creator><creator>GAMMON, PATRICIA JENEY</creator><creator>BROWN, VICKI L.</creator><creator>MARCH, JOHN S.</creator><general>Elsevier Inc</general><general>Lippincott</general><general>Elsevier BV</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20010501</creationdate><title>Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open Trial</title><author>COMPTON, SCOTT N. ; GRANT, PAUL J. ; CHRISMAN, ALLAN K. ; GAMMON, PATRICIA JENEY ; BROWN, VICKI L. ; MARCH, JOHN S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-b78bbcbf0d953c6ec733283b3a4cf81f1ae038ffcd9758e02540060eb044ceaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Antidepressive Agents - administration & dosage</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Anxiety</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Children & youth</topic><topic>Clinical trials</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmaceuticals</topic><topic>Pharmacology. Drug treatments</topic><topic>pharmacotherapy</topic><topic>preadolescent</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>sertraline</topic><topic>Sertraline - administration & dosage</topic><topic>Sertraline - therapeutic use</topic><topic>Social Adjustment</topic><topic>social anxiety disorder</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COMPTON, SCOTT N.</creatorcontrib><creatorcontrib>GRANT, PAUL J.</creatorcontrib><creatorcontrib>CHRISMAN, ALLAN K.</creatorcontrib><creatorcontrib>GAMMON, PATRICIA JENEY</creatorcontrib><creatorcontrib>BROWN, VICKI L.</creatorcontrib><creatorcontrib>MARCH, JOHN S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COMPTON, SCOTT N.</au><au>GRANT, PAUL J.</au><au>CHRISMAN, ALLAN K.</au><au>GAMMON, PATRICIA JENEY</au><au>BROWN, VICKI L.</au><au>MARCH, JOHN S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open Trial</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>2001-05-01</date><risdate>2001</risdate><volume>40</volume><issue>5</issue><spage>564</spage><epage>571</epage><pages>564-571</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>The aim of this open-label study was to assess the therapeutic benefits, response pattern, and safety of sertraline in children with social anxiety disorder.
Fourteen outpatient subjects with a primary Axis I diagnosis of social anxiety disorder were treated in an 8-week open trial of sertraline. Diagnostic and primary outcome measures included the Anxiety Disorders Interview Schedule for Children, Clinical Global Impressions scale (CGI), Social Phobia and Anxiety Inventory for Children, and a standardized behavioral avoidance test.
As measured by the CGI (Improvement subscale), 36% (5/14) of subjects were classified as treatment responders and 29% (4/14) as partial responders by the end of the 8-week trial. A significant clinical response appeared by week 6. Self-report and behavioral measures showed significant clinical improvement into normal range across all domains measured. The mean dose of sertraline was 123.21 ± 37.29 mg per day. Sertraline was generally well tolerated.
In open treatment, sertraline resulted in significant improvement in symptoms of childhood social anxiety disorder. Absolute response rates varied depending on rating scales used. Findings from this study are sufficiently strong to warrant a future multisite, randomized, double-blind, placebo-controlled trial of sertraline for treatment of childhood social anxiety disorder.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>11349701</pmid><doi>10.1097/00004583-200105000-00016</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-8567 |
| ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 2001-05, Vol.40 (5), p.564-571 |
| issn | 0890-8567 1527-5418 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70838471 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals; Journals@Ovid Complete |
| subjects | Adolescent Antidepressive Agents - administration & dosage Antidepressive Agents - therapeutic use Anxiety Anxiety Disorders - drug therapy Biological and medical sciences Child Children & youth Clinical trials Drug Administration Schedule Female Humans Male Medical sciences Neuropharmacology Pharmaceuticals Pharmacology. Drug treatments pharmacotherapy preadolescent Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology sertraline Sertraline - administration & dosage Sertraline - therapeutic use Social Adjustment social anxiety disorder Treatment Outcome |
| title | Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A59%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sertraline%20in%20Children%20and%20Adolescents%20With%20Social%20Anxiety%20Disorder:%20An%20Open%20Trial&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=COMPTON,%20SCOTT%20N.&rft.date=2001-05-01&rft.volume=40&rft.issue=5&rft.spage=564&rft.epage=571&rft.pages=564-571&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1097/00004583-200105000-00016&rft_dat=%3Cproquest_cross%3E73091482%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212597664&rft_id=info:pmid/11349701&rft_els_id=S0890856709606870&rfr_iscdi=true |